gdx012
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 13, 2021 (NCT05001451)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05886491 | Phase 1/Phase 2 (Phase 2) | Jul 11, 2023 | Takeda |
| NCT05001451 | Phase 1 | Aug 13, 2021 | GammaDelta Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GammaDelta Therapeutics | For profit | 1 | 1 | 1 | 2021 |
| Takeda | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1